Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.

Item request has been placed!

Item request cannot be made.

Processing Request

Read Online Read More Add to Saved list

Author(s): Radsak M;Radsak M; Platzbecker U; Platzbecker U; Schmidt CS; Schmidt CS; Hofmann WK; Hofmann WK; Nolte F; Nolte F
Source:
European journal of haematology [Eur J Haematol] 2017 Aug; Vol. 99 (2), pp. 112-118. Date of Electronic Publication: 2017 Apr 20.
Publication Type:
Journal Article; Review
Language:
English

Additional Information
- Source:
  Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE
- Publication Information:
  Publication: <2005->: Oxford : Blackwell
  Original Publication: Copenhagen : Munksgaard, c1987-
- Subject Terms:
  Antimetabolites, Antineoplastic/*adverse effects ; Azacitidine/*adverse effects ; Infections/*etiology ; Myelodysplastic Syndromes/*complications; Antibiotic Prophylaxis ; Antimetabolites, Antineoplastic/therapeutic use ; Azacitidine/therapeutic use ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Infection Control ; Infections/diagnosis ; Infections/drug therapy ; Morbidity ; Mortality ; Myelodysplastic Syndromes/drug therapy ; Neutropenia/complications ; Neutropenia/etiology
- Abstract:
  Myelodysplastic Syndromes are oligo-clonal stem cell disorders that are associated with cytopenias in the peripheral blood. Major causes for morbidity and mortality in myelodysplastic syndromes (MDS) patients are infections mostly due to bacteria or fungi. Beside leucopenia per se in affected patients, function of white blood cells particularly that of neutrophils seems to be impaired. Here we summarize the available data on infections in MDS patients in general and particularly those treated with 5-azacitidine.
  (© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Contributed Indexing:
  Keywords: 5-azacitidine; infection; myelodysplastic syndromes; socioeconomics and ethics; supportive care
- Accession Number:
  0 (Antimetabolites, Antineoplastic)
  143011-72-7 (Granulocyte Colony-Stimulating Factor)
  M801H13NRU (Azacitidine)
- Publication Date:
  Date Created: 20170322 Date Completed: 20180326 Latest Revision: 20191210
- Publication Date:
  20240105
- Accession Number:
  10.1111/ejh.12883
- Accession Number:
  28321924

Comments

No Comments.